Study wrapper · #946
The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.
Hudanich M, Smith SN, Marino A, et al. Cureus. 2025.
DOI: 10.7759/cureus.93104PubMed: 41141001
Editor's note
This scoping review examines incretin mimetics as a possible option for insulin resistance in PCOS, reporting improvements in weight and insulin sensitivity across GLP-1, dual, and triple agonists. The evidence is early and heterogeneous, and the authors call for research into mechanisms and optimal use. A useful signal for an off-label application that warrants cautious framing.
Plain-language abstract
A scoping review found that GLP-1-based agents, including semaglutide, tirzepatide, and retatrutide, were associated with improvements in weight and insulin sensitivity in women with polycystic ovarian syndrome compared with standard therapy.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026